Andrisani, Gianluca
 Distribuzione geografica
Continente #
EU - Europa 851
NA - Nord America 776
AS - Asia 226
AF - Africa 2
Totale 1.855
Nazione #
US - Stati Uniti d'America 770
DE - Germania 432
CN - Cina 106
SE - Svezia 94
UA - Ucraina 90
IT - Italia 64
SG - Singapore 59
GB - Regno Unito 52
FR - Francia 48
IE - Irlanda 28
IN - India 23
FI - Finlandia 21
ID - Indonesia 17
TR - Turchia 11
BE - Belgio 7
CA - Canada 6
IR - Iran 4
GR - Grecia 3
JP - Giappone 3
PL - Polonia 3
RU - Federazione Russa 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
NL - Olanda 2
TW - Taiwan 2
CH - Svizzera 1
GE - Georgia 1
HU - Ungheria 1
Totale 1.855
Città #
Chandler 172
Jacksonville 76
Ashburn 58
San Mateo 51
Singapore 47
Dearborn 43
Ann Arbor 34
Cattolica 32
New York 32
Dublin 28
Nürnberg 24
Nanjing 23
Munich 20
Jakarta 17
Milan 17
Wilmington 17
Lawrence 15
Houston 14
Lancaster 14
Beijing 13
Boston 13
Bremen 12
Izmir 10
Leawood 8
Seattle 8
Shenyang 8
Woodbridge 8
Brussels 7
London 6
Los Angeles 6
Fairfield 5
Mountain View 5
Nanchang 5
Shanghai 5
Ardabil 4
Hebei 4
Jiaxing 4
Marseille 4
Augusta 3
Changsha 3
Costa Mesa 3
Detroit 3
Edinburgh 3
Helsinki 3
Kraków 3
Redwood City 3
Rome 3
Simi Valley 3
Toronto 3
University Park 3
Washington 3
Abidjan 2
Athens 2
Berlin 2
Boardman 2
Changchun 2
Corsico 2
Frankfurt am Main 2
Fremont 2
Guangzhou 2
Hangzhou 2
Hefei 2
Kunming 2
Millbury 2
Moscow 2
Norwalk 2
Princeton 2
Sofia 2
Taipei 2
Tianjin 2
Ahmedabad 1
Amsterdam 1
Andover 1
Bern 1
Budapest 1
Clearwater 1
Delhi 1
Fuzhou 1
Ipswich 1
Jinan 1
Kyiv 1
Landshut 1
Monmouth Junction 1
Montreal 1
Montréal 1
Novara 1
Ocean Grove 1
Ottawa 1
Paris 1
Pisa 1
Pittsburgh 1
Pune 1
Quzhou 1
Raritan 1
Redmond 1
Ribera 1
San Jose 1
Shaoxing 1
Tappahannock 1
Tbilisi 1
Totale 976
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 154
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 145
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 144
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 140
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 138
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 136
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 124
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 121
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 117
Use of infliximab in particular clinical settings: management based on current evidence. 101
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 92
Giant arteriovenous malformation of the colon mimicking lipoma 85
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 78
Management of perianal fistulas in Crohn's disease: an up-to-date review 77
Mucosal healing in ulcerative colitis: surveillance or colectomy? 72
AID in aging and autoimmune diseases 71
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 67
Totale 1.862
Categoria #
all - tutte 6.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.134


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020165 0 0 0 0 0 46 23 13 20 8 33 22
2020/2021152 2 19 3 19 19 3 17 9 22 1 34 4
2021/2022194 20 18 4 41 3 1 2 44 4 1 19 37
2022/2023387 52 53 21 78 33 45 8 26 53 2 10 6
2023/2024164 8 44 5 12 3 32 5 16 2 5 15 17
2024/2025102 4 16 28 5 42 7 0 0 0 0 0 0
Totale 1.862